Company Description
Jupiter Neurosciences is a clinical stage research and development pharmaceutical company.
The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation.
The product, called JOTROL™, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as ALS which is in an early development stage.
In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimer’s disease with TBI/concussions and Covid-19 in early development stages.
Based on available scientific literature, we believe that JOTROL™ is the first and only resveratrol product in the world that delivers a therapeutically effective dose of resveratrol in the blood stream without causing gastrointestinal side effects.
We believe that JOTROL™ is a safe oral medication, based on existing documented safety profile of resveratrol and the results from our Phase I study which did not result in any serious adverse events.
We recently submitted a grant application to NIA for full funding for the duration of the study, of a Phase II trial in Mild Cognitive Impairment (MCI) and early Alzheimer’s disease.
We expect to receive their funding decision in H1 of 2022.
| Country | United States |
| Founded | 2015 |
| Industry | Pharmaceuticals |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Christer Rosén |
Contact Details
Address: 1001 North US HWY 1, Suite 504 Jupiter, FL 33477 United States | |
| Phone | (561) 406-6154 |
| Website | jupiterneurosciences.com |
Stock Details
| Ticker Symbol | JUNS |
| Exchange | NASDAQ |
| Reporting Currency | USD |
| CIK Code | 0001679628 |
| Employer ID | 47-4828381 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 8-K | Current Report |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 15, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Oct 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 13, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Sep 4, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |